News
MedAlliance Acquired by Cordis for up to USD 1.135 Billion
2 October 2023 – Swiss-based medical technology company MedAlliance has been acquired by Cordis for a 2022 investment of $35M and a 2023 upfront closing payment of $200M, together with regulatory achievement milestones of up to $125M and commercial milestones of up to $775M through 2029, for a total consideration of up to $1.135 Billion.
MedAlliance Announces Enrollment of over 1,660 Patients in Landmark SELUTION DeNovo Study
14 September 2023 – MedAlliance has announced enrollment of over 1,660 patients in its ground-breaking SELUTION DeNovo coronary randomized study. Recruitment is now half way towards a planned 3,326 patients. SELUTION DeNovo compares the treatment strategy using a novel sirolimus drug-eluting balloon [SELUTION SLR], versus any limus drug-eluting stent [DES].
MedAlliance Announces Enrollment of First Patient in SELUTION SLR LOVE-DEB Coronary Study
6 September 2023 – The first patient has been enrolled in a UK study of large vessel de novo coronary artery disease treated with SELUTION SLR™. This is a trial initiated by physicians at the Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust, which is where the first patient was enrolled. SELUTION SLR is a novel sirolimus-eluting balloon that provides a controlled sustained release of drug, similar to a drug-eluting stent (DES).
Enrollment Completed in SAVE Trial with SELUTION SLR for Treatment of AV Fistulas in Renal Dialysis Patients
14 August 2023 – MedAlliance has announced completion of patient enrollment in the SAVE Clinical Trial with the SELUTION SLR™ 018 DEB (drug-eluting balloon) for the treatment of failed AVF (arteriovenous fistulas) in renal dialysis patients. SELUTION SLR is a novel sirolimus-eluting balloon that provides a controlled sustained release of drug, similar to a drug-eluting stent (DES).
Excellent 12-Month Results from SELUTION SFA Trial Presented at JET
30 May 2023 – 12-month results from the SELUTION SFA trial have been presented for the first time at the Japan Endovascular Treatment (JET) Conference in Tokyo. The objective of this study was to assess the safety and efficacy of SELUTION SLR™, MedAlliance’s novel sirolimus-eluting balloon, for endovascular therapy of de novo and non-stented restenotic lesions in the superficial femoral artery (SFA) and popliteal artery (PA).